search

Active clinical trials for "Carcinoma, Renal Cell"

Results 1371-1380 of 1644

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is...

Kidney Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and biological therapy in treating patients with kidney cancer that is metastatic or cannot be removed surgically.

Unknown status3 enrollment criteria

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor...

Stage IV Non-small Cell Lung CancerStage IV Melanoma2 more

Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis system, aiming to answer two different study questions: Safety, tolerability and effectiveness of the device. Safety, tolerability and effectiveness of the device, employed as monotherapy, or combined with Nivolumab.

Unknown status65 enrollment criteria

Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

The investigators reported previously that epigenetic activation of organic cation transporter (OCT2) by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in xenografts. The objective of this phase II clinical trial is to investigate the efficacy and safety of sequential combination therapy with decitabine and oxaliplatin in patients with relapsed/metastatic renal cell carcinoma who progressed on standard of care.

Unknown status23 enrollment criteria

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Renal Cell Cancer Metastatic

This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety of CM082 in combination with everolimus in Chinese patients with advanced renal cell carcinoma. The primary endpoint is progression-free survival.

Unknown status18 enrollment criteria

Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma...

Metastatic Renal Cell CarcinomaKidney Neoplasm2 more

The purpose of the open-label INDIGO-study is to examine whether a first line individualized treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible. Moreover, to involve the patient further in their treatment via patient-reported outcomes (PRO) measurements in a value-based healthcare setup with simultaneous analyses of the financial costs of this strategy. The patients are assigned into 4 treatment arms according to the results of their DNA and RNA analyses. All patients receive electronic questionnaires regarding symptoms and side effects weekly and questionnaires regarding quality of life monthly. Based on each patient's answers of the questionnaires the patient receives advices in the app to reduce the symptoms and side effects or the patient is instructed to contact the hospital. The hypothesis: Basing the choice of first-line treatment for DNA mutations and RNA profiles in a heterogeneous patient population increases the overall response rate for the total population to 30% compared to 10% for historical cohorts.

Unknown status33 enrollment criteria

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)...

Renal Cell Carcinoma

Combined sunitinib and bevacizumab in advanced renal cell carcinoma.

Unknown status36 enrollment criteria

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor...

Renal Cell CancerAdvanced Renal Cell Cancer

Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in patients with advanced renal cell cancer (RCC).

Unknown status15 enrollment criteria

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell...

Renal Cell Carcinoma

Single arm, open label, phase II trial. Participants to undergo biopsy of primary tumour followed by 8 weeks of nivolumab therapy followed by nephrectomy. Nivolumab to be continued post-operatively

Unknown status28 enrollment criteria

Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney...

Kidney Cancer

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether undergoing immediate surgery or surgery after sunitinib malate is more effective in treating patients with metastatic kidney cancer. PURPOSE: This randomized phase III trial is studying immediate surgery to see how well it works compared with surgery after sunitinib malate in treating patients with metastatic kidney cancer.

Unknown status53 enrollment criteria

Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

To evaluate the efficacy and safety of sunitinib in non-clear cell type renal cell carcinoma with the exception of pure sarcomatoid carcinoma and collecting duct carcinoma

Unknown status16 enrollment criteria
1...137138139...165

Need Help? Contact our team!


We'll reach out to this number within 24 hrs